Briakinumab vs placebo
Failure to maintain remission · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in failure to maintain clinical remission compared with placebo (low certainty).
1 finding from 1 review
- Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 0.84 [0.58, 1.2]1 study · 99 participantsLow